Cambridge Cognition announces formation of new Scientific Advisory Board

Cambridge Cognition Holdings plc (AIM: COG) has established a Scientific Advisory Board to provide scientific counsel and market insights, focusing on integrating blood-based biomarkers, collaborative cognitive assessments, and diversity in clinical trials. Chaired by Liam Kaufman, the board includes Professor Judith Jaeger, Professor John Harrison, and Francesca Cormack.

Professor Jaeger, a neuropsychologist with extensive experience in clinical trials, brings expertise in early-phase projects and regulatory meetings.

Professor Harrison, known for his work in cognitive skills enhancement, has aided over 80 CNS drug development organizations and contributed to Alzheimer’s disease studies. Matthew Stork, CEO of Cambridge Cognition, highlights the board's role in aligning with evolving trends in CNS research.

Professor Jaeger looks forward to leveraging cognitive science and Winterlight Labs’ capabilities in therapeutic development. Professor Harrison emphasizes his familiarity with CANTAB and Winterlight Labs’ technologies, expressing excitement to shape their future use. The board's formation underscores Cambridge Cognition's commitment to advancing cognitive science and meeting customer needs in an evolving landscape.